announced today the termination of a license agreement for AAT-007 & AAT-008 (EP4 Antagonist) for global immuno-oncology as of March 20, 2024, which was originally signed with Ikena Oncology Inc (Headquarters: Massachusetts, USA; hereinafter referred to as “Ikena”) on December 14, 2017. Clinical trials have shown that AAT-007 was effective and well tolerated in microsatellite stable colorectal cancer, as previously announced (https://askat-inc.com/news/ikena-oncology-presented-results-of-a-clinical-trialof-grapiprant-aat-007-ik-007-in-atients-with-advanced-microsatellite-stable-colorectal-cancer/),. This termination is due to a change in Ikena’s R&D strategy. AskAt will continue to implement strategic options for AAT-007 and AAT-008, including the selection of a new partner.
